Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0262471 (ENT)
 5,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

(1) Moxifloxacin is the fourth fluoroquinolone to be licensed in France with indications covering ENT and respiratory tract infections. (2) In community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis, moxifloxacin seems no more effective than other fluoroquinolones available in France (with which it has not been compared) or the other antibiotics with which it has been compared. (3) Moxifloxacin has the usual adverse effects of fluoroquinolones, but carries a greater risk of QT prolongation than ciprofloxacin, levofloxacin and ofloxacin.
 ...
PMID:Moxifloxacin: new preparation. A me-too with more cardiac risks. 1246 94

The comparison of the efficacy of a number of antibacterial drugs in acute pyoinflammatory ENT diseases allowed the authors to recommend moxifloxacin as most effective in acute purulent ENT pathology. Moxifloxacin demonstrated its superiority in seeding (the highest sensitivity of the bacteria to this antibiotic), in the speed of development of the bactericidal action and in treatment results. The drug had no significant side effects.
 ...
PMID:[A comparative analysis of antibiotics efficacy in acute ENT infections]. 1624 67